Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Liabilities (2020 - 2025)

Tango Therapeutics has reported Total Liabilities over the past 6 years, most recently at $52.5 million for Q4 2025.

  • Quarterly results put Total Liabilities at $52.5 million for Q4 2025, down 55.11% from a year ago — trailing twelve months through Dec 2025 was $52.5 million (down 55.11% YoY), and the annual figure for FY2025 was $52.5 million, down 55.11%.
  • Total Liabilities for Q4 2025 was $52.5 million at Tango Therapeutics, up from $50.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for TNGX hit a ceiling of $191.1 million in Q3 2022 and a floor of $6.1 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $145.6 million (2023), compared with a mean of $124.2 million.
  • Biggest five-year swings in Total Liabilities: surged 2667.87% in 2021 and later plummeted 59.35% in 2025.
  • Tango Therapeutics' Total Liabilities stood at $155.4 million in 2021, then increased by 20.32% to $187.0 million in 2022, then dropped by 20.07% to $149.5 million in 2023, then fell by 21.73% to $117.0 million in 2024, then tumbled by 55.11% to $52.5 million in 2025.
  • The last three reported values for Total Liabilities were $52.5 million (Q4 2025), $50.1 million (Q3 2025), and $102.9 million (Q2 2025) per Business Quant data.